Methotrexate — chemotherapy from the antimetabolite group

What Methotrexate is in simple patient language

Methotrexate goes by MTX in most oncology units. It has been around long enough that its role is well established. It belongs to the antimetabolite class — a group of drugs that starve dividing cells of the materials they need to copy DNA. The cell runs out of what it needs and cannot proceed.

Two things tend to come as a surprise. First, the dose. MTX at the amount a rheumatologist prescribes weekly and MTX at the amount used to treat bone cancer are not comparable experiences — same molecule, entirely different treatment. Second, leucovorin. Most patients have not heard of it before their first high-dose cycle. It is a separate drug given in the hours and days after the infusion, specifically to limit damage to healthy tissue. Without it, high-dose treatment would not be survivable. These are worth knowing before the drip goes in.

Whether methotrexate is right at this dose at this point depends on the condition, the kidneys, and what other tablets the patient is already on. Diagnosis is where the conversation starts, not where it ends.

How Methotrexate works

MTX does not go after DNA directly. Inside the cell it blocks a specific enzyme that sits early in the folate pathway — the chain of reactions cells use to produce the raw nucleotides needed for replication. Cut off that supply and the copying process stalls.

Fast-dividing cells hit the wall first. That includes tumour cells, but also the gut lining, the marrow, and the lining of the mouth. Most side effects come from there.

At the low doses used in rheumatology the dominant effect is anti-inflammatory, not cytotoxic. Folate metabolism touches immune regulation as well as cell division. At oncology doses the cytotoxic effect takes over. The molecule is the same; the dose determines what it is primarily doing.

Which conditions may be treated with Methotrexate

Methotrexate appears across oncology and some other specialties. The oncology uses are the focus here.

• acute lymphoblastic leukaemia — used at multiple points in the treatment course, including directly into the spinal fluid for CNS protection
• osteosarcoma — very high doses before and after surgery, always with leucovorin given afterwards
• non-Hodgkin lymphoma — in combination protocols and in regimens targeting the central nervous system
• primary CNS lymphoma — high-dose IV is the main approach because the drug crosses into the brain
• gestational trophoblastic disease — low-dose treatment for low-risk cases, where it can be curative
• bladder cancer — part of the MVAC combination regimen
• head and neck cancers in selected protocols

Diagnosis opens the conversation. Subtype, disease extent, kidney function, what has already been tried and how it was tolerated — those are what shape the real decision.

When Methotrexate can be especially relevant

Certain clinical situations bring it into focus.

• ALL — across induction, consolidation and maintenance, and as CNS prophylaxis given into the spinal canal
• osteosarcoma — before and after surgery, as part of a protocol that typically runs for many months
• primary CNS lymphoma — high-dose IV is the backbone because the drug crosses into the brain
• gestational trophoblastic disease — where low-dose single-agent treatment is often enough to cure
• lymphoma protocols that include a CNS component
• second opinion requests on whether the proposed dose, route or schedule fits the specific situation

Treatment into the spinal canal and treatment into a vein are not the same thing. Different route, different purpose, different complications. That distinction matters and should be part of the conversation upfront.

What should be checked before treatment

The team needs a proper picture before the first dose — not just the protocol name.

• diagnosis, subtype and treatment goal
• kidney function — methotrexate exits almost entirely through renal excretion; checked before every high-dose cycle
• liver function — baseline matters and cumulative exposure over time is tracked
• full blood count
• fluid in the chest or abdomen — pockets of fluid hold the drug and slow clearance
• all current medications — several drug classes interfere with how methotrexate clears
• general physical condition and performance status
• fertility plans when relevant

Kidney function is more critical here than with almost any other oncology drug. Methotrexate depends on the kidneys to leave the body. Even a modest drop in kidney performance can keep levels elevated far longer than planned and turn a manageable infusion into a toxic event.

How treatment with Methotrexate is usually given

The route depends on what is being treated. Into a vein for systemic disease. Into the spinal canal for CNS disease or prophylaxis. By mouth at low doses in some maintenance protocols.

At high oncology doses the infusion runs over several hours, followed by heavy IV fluid and leucovorin starting 24 hours in. Blood levels are drawn repeatedly until they fall to a confirmed safe point. Leucovorin continues until that threshold is reached. Doses across different indications differ enormously.

During treatment the team monitors:

• methotrexate blood levels after every high-dose infusion — leucovorin dosing follows those numbers
• kidney function before each cycle and during the infusion
• urine acidity — alkaline urine helps the drug dissolve and leave the body
• full blood count
• liver enzymes at regular intervals
• mouth and gut symptoms — early sores suggest levels are running higher than expected
• imaging at planned points to assess response

Delays and dose changes happen and are not a sign of failure. Kidney numbers, drug levels, mucositis — any of these can shift timing or amount. Asking why is always reasonable.

Possible side effects

Mouth sores tend to be what patients find hardest — and at oncology doses, that concern is usually well founded.

• mucositis — mouth and throat sores, ranging from uncomfortable to severe depending on dose and clearance speed
• nausea and vomiting — significant at higher doses; antiemetics are given routinely
• marrow suppression — white cells and platelets fall, raising infection and bleeding risk
• liver enzyme rises — common; with long-term repeated exposure, liver scarring is a known concern
• kidney damage — when clearance slows and levels stay high longer than intended
• fatigue
• skin becomes more sensitive to sunlight
• hair thinning at higher doses

Rare but serious:

• acute kidney injury when the drug does not clear on schedule — why blood levels are drawn repeatedly after each high-dose infusion
• nervous system effects — more common after spinal administration or very high IV doses; headache, confusion, and in some cases cognitive changes that appear weeks or months later
• lung inflammation — can appear at any dose; new breathlessness during treatment is always investigated promptly

Nervous system changes after spinal administration deserve the most active tracking. Memory lapses, concentration problems, mood shifts that develop during or after treatment — not just at the time of injection — should be raised with the team straight away.

When to contact a doctor urgently

Some things during methotrexate treatment should not wait for the next scheduled visit.

• fever or chills — same-day call regardless of how the patient otherwise feels
• mouth sores severe enough to make swallowing impossible
• new breathlessness or a dry cough
• urine output dropping noticeably, especially after a high-dose infusion
• unusual bruising or bleeding
• headache, confusion or personality change after spinal administration
• any sudden or unexplained shift in general condition

When clearance falls behind after a high-dose infusion, drug levels stay up and damage continues past the planned window. Dropping urine output or a blood level higher than expected is a reason to call the team that day, not to wait.

Why Methotrexate is not right for every patient

Even when the diagnosis fits and the drug is standard for that condition, methotrexate does not suit every patient at every point.

• meaningful kidney impairment — the main reason high-dose treatment cannot proceed
• active liver disease or substantial pre-existing liver damage
• uncontrolled fluid in the chest or abdomen that has not been drained
• medications that block the same clearance routes and cannot safely be stopped
• pregnancy — the drug interferes with embryo development; contraception is required throughout treatment and for a set period after it ends
• situations where a different drug or route fits the clinical picture better

Methotrexate reacts badly with more drugs than most patients expect. Painkillers from the ibuprofen family slow the rate at which the kidneys remove the drug. Certain penicillins do the same. Some tablets taken for stomach acid affect renal excretion. Trimethoprim, used as an antibiotic, hits the same enzyme the drug targets and makes the effect stronger. Going through every tablet, capsule and supplement before each cycle is not a bureaucratic step — it is how serious toxicity gets prevented.

Can Methotrexate be combined with other treatments

Rarely given on its own outside a handful of specific situations. In most oncology protocols it runs alongside other drugs.

• cytarabine — used alongside methotrexate in CNS lymphoma and as part of spinal prophylaxis in leukaemia
• vincristine, doxorubicin and cisplatin — combined in osteosarcoma protocols
• rituximab — added in CNS lymphoma
• cyclophosphamide and other agents — in leukaemia maintenance and lymphoma regimens
• leucovorin — not a treatment partner but an essential part of every high-dose protocol

What methotrexate is combined with changes the full picture. Cytarabine adds marrow suppression. Cisplatin adds hearing and kidney concerns. Leucovorin is what makes high doses possible at all.

What no quick response can mean

Response is not measured after one cycle. It takes several cycles, then imaging, markers and clinical assessment together. A single scan or a single blood result is rarely enough to draw conclusions.

If the disease is clearly progressing, toxicity has become unmanageable, or the regimen is not achieving what it was designed for — the plan needs reviewing. Methotrexate is a tool inside a strategy. When the strategy needs updating, that conversation should happen with the treating oncologist rather than being deferred.

Oncology consultation in Israel

Tel Aviv Medical Clinic offers oncology consultations and second opinions for patients on a methotrexate-based regimen or considering one. Useful when the dose or route has not been properly explained, when a complication has arisen that has not been addressed, when a drug interaction concern has come up, or when the patient wants to understand what alternatives exist.

The consultation can cover:

• pathology and imaging review
• previous treatment history and response
• assessment of current toxicities and what can be adjusted
• review of drug interactions and clearance concerns
• second opinion on the current protocol
• questions to bring back to the treating oncologist

We do not replace the treating doctor. We help the patient arrive at the next conversation knowing what to ask.

Frequently asked questions — answered by Dr. Stefanska and Dr. Meerovich

1. Why is leucovorin given after methotrexate and what happens if doses are missed?

Leucovorin is a folate compound that bypasses the enzyme methotrexate blocks. Normal cells keep functioning while drug levels are still high. Cancer cells do not benefit the same way — they handle leucovorin differently. Missing doses after a high infusion allows the drug to keep damaging normal tissue past the intended window. Gut lining, marrow, kidneys. The timing follows blood levels, not a clock on the wall.

2. Why is kidney function tested so frequently during treatment?

Methotrexate leaves the body almost entirely through one route — the kidneys. Slow that down, even slightly, and levels stay up longer than planned. Leucovorin cannot fully compensate. At high doses the result is gut damage, marrow failure, and kidney injury on top of each other. The gap between a working level and a harmful one closes fast when renal function drops. Testing before each cycle and during the infusion is how that gets caught before it becomes a crisis.

3. What is the difference between spinal and intravenous methotrexate?

IV methotrexate goes into the bloodstream and reaches most of the body. The central nervous system sits behind a barrier that most drugs — even at high IV doses — do not cross reliably. Spinal administration puts the drug directly into the cerebrospinal fluid through a needle in the lower back. No barrier to cross. The two approaches treat different problems, produce different complications, and are not interchangeable.

4. Which medications cause problems when taken with methotrexate?

The ibuprofen group — and other drugs in that painkiller class — compete with methotrexate for the same exit pathway through the kidneys. Levels rise. Some penicillin antibiotics do the same. Certain tablets prescribed for acid reflux reduce how well the kidneys push methotrexate out. Trimethoprim targets the same enzyme the drug targets and amplifies the whole effect. None of this is labelled obviously. The only way to find the conflicts is to go through every medication, supplement and herbal product before each cycle.

5. What documents should I bring for a second opinion?

Pathology report, recent scans, surgery notes if relevant, the full list of treatments given and when, methotrexate blood levels from previous cycles if available, recent kidney and liver results. A specific account of any complications — which cycle, what happened, how severe, how it was managed. A complete medication list. For patients who have had spinal treatment, any neurological symptoms that appeared and whether they resolved. That level of detail is what makes the consultation genuinely useful.

Important information

This page gives general medical information. It is not a personal treatment plan. Methotrexate should be discussed only after review of the diagnosis, stage, kidney and liver function, current medications and the patient’s overall condition.

Do not start, stop or change chemotherapy without your treating oncologist.

For consultation about Methotrexate treatment:

📞 +972-73-374-6844

📧 [email protected]

💬 WhatsApp: +972-52-337-3108